Jeff Bezos just opened Blue Origin to outside investors for the first time, and his own $2 billion investment may be the strongest signal yet that he believes the company's biggest growth is still ahead.
Teva Pharmaceutical Industries (NYSE:TEVA) said its internally developed anti-IL-15 antibody produced encouraging 24-week efficacy results in a phase 1b proof-of-concept study for vitiligo, as the company highlighted the program as part of its broader shift toward a biopharma-focused growth strategy
Barchas maintains 211,763 residual shares through direct and indirect holdings following execution under a Rule 10b5-1 trading plan adopted in March 2026.
Dr. Reddy's Laboratories (NYSE:RDY) said a scale-up issue tied to the active pharmaceutical ingredient for its semaglutide injection will temporarily delay commercial supplies, though management emphasized that products already supplied to the market are not affected and do not raise patient safety
J.P. Morgan just outlined why a SpaceX-Tesla merger could make strategic sense on paper. It also got into why investors shouldn't mistake that for a likely deal.
Executed under a pre-arranged Rule 10b5-1 plan, the transaction reduces Radke's stake by just 0.28%, leaving him with ~28.6 million shares worth $379 million.
